Inspire Medical Systems (INSP) to Release Earnings on Wednesday

Inspire Medical Systems (NYSE:INSP) is expected to be posting its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect Inspire Medical Systems to post earnings of $0.70 per share and revenue of $264.0190 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 5:00 PM ET.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($0.15) by $0.53. The business had revenue of $224.50 million during the quarter, compared to the consensus estimate of $220.39 million. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The company’s revenue was up 10.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.60 earnings per share. On average, analysts expect Inspire Medical Systems to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Inspire Medical Systems Price Performance

Shares of NYSE:INSP opened at $72.06 on Wednesday. Inspire Medical Systems has a one year low of $70.77 and a one year high of $203.12. The company has a market cap of $2.09 billion, a price-to-earnings ratio of 49.02, a PEG ratio of 7.41 and a beta of 0.74. The firm has a 50 day simple moving average of $103.51 and a 200 day simple moving average of $94.05.

Insider Activity

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director directly owned 26,046 shares in the company, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 2.30% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

Several hedge funds have recently made changes to their positions in INSP. Royal Bank of Canada lifted its holdings in shares of Inspire Medical Systems by 16.0% during the first quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after purchasing an additional 4,528 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Inspire Medical Systems during the 1st quarter valued at approximately $524,000. Goldman Sachs Group Inc. raised its stake in Inspire Medical Systems by 57.9% during the first quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after buying an additional 18,857 shares during the last quarter. Marshall Wace LLP raised its stake in Inspire Medical Systems by 3.8% during the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after buying an additional 577 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in Inspire Medical Systems in the second quarter worth $931,000. 94.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on INSP. Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, October 27th. Jefferies Financial Group restated a “hold” rating and set a $85.00 price target (down previously from $160.00) on shares of Inspire Medical Systems in a research note on Friday, October 24th. Wells Fargo & Company lowered their price objective on Inspire Medical Systems from $160.00 to $145.00 and set an “overweight” rating for the company in a research note on Wednesday, January 14th. Morgan Stanley reissued an “equal weight” rating and set a $130.00 price target (up from $105.00) on shares of Inspire Medical Systems in a research report on Tuesday, December 2nd. Finally, KeyCorp restated a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, November 4th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $133.47.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.